Slide 1: Q2 2026 results
Q2 2026 results Committed to solid profitable growth August 5, 2026
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Q2 2026: Solid performance exceeding outlook
Q2 2026: Solid performance exceeding outlook Growth Q2 2026 net sales ahead of outlook with growth pillars driving performance $535 mn ($531 mn CER) • 0% CER, ahead of the outlook for ~-2% CER decline Net sales • Sales from growth pillars increased 5% CER, led by Sample tech, QIAcuity and QDI 0% CER
Slide 4: Q2 2026: Sales performance and key developments
Q2 2026: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) 0% Sample • +9% CER growth, +3% CER growth excl. Parse CER(1) technologies • Automated consumables delivered high teens CER growth 534 535 • +1% CER growth with solid trends outsid
Slide 5: Q2 2026: Portfolio developments
Q2 2026: Portfolio developments Sample technologies: QIAGEN Digital Insights: QIAstat-Dx: Expanding automated sample preparation Accelerating biomedical research Advancing syndromic testing solutions Progressing rollout of new automation NVIDIA collaboration to advance AI Launch of QIAstat-Dx panels
Slide 6: Q3 and FY 2026: Outlook and assumptions
Q3 and FY 2026: Outlook and assumptions (As of August 5, 2026) Q3 2026 outlook FY 2026 outlook Net sales ~+1-2% CER ~+1-2% CER Anticipated currency impact(1) Negative impact of ~-1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS(2) ≥$0.62 CER ≥$2.43 CER Anticipated currency impact(1) Neutral Neu
Slide 7: Appendix
QIAGEN Appendix
Slide 8: Disciplined capital allocation to drive long-term value
Disciplined capital allocation to drive long-term value Profitable targeted investments Annual dividend Organic into growth pillars and digitization to fuel profitable Dividend approval at the AGM in investments June 2026 business expansion $0.35 dividend per share (~$72 mn payment in July 2026) Foc
Slide 9: Q2 2026: Consolidated Statements of Income (unaudited)
Q2 2026: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended June 30, 2026 June 30, 2025 Net sales 535,040 533,540 Cost of sales: Cost of sales 181,973 185,951 Acquisition-related intangible amortization 12,681 13,303 Total cost of
Slide 10: H1 2026: Consolidated Statements of Income (unaudited)
H1 2026: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Six months ended Six months ended June 30, 2026 June 30, 2025 Net sales 1,027,360 1,016,996 Cost of sales: Cost of sales 351,432 347,245 Acquisition-related intangible amortization 25,939 26,784 Total cost of
Slide 11: 2026: Quarterly sales by product group
2026: Quarterly sales by product group Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 170 13% 9% 182 9% 9% 352 11% 9% Diagnostic solutions(1) 185 -1%
Slide 12: 2026: Quarterly sales by product type and region
2026: Quarterly sales by product type and region Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 445 2% -1% 484 2% 1% 928 2% 0% revenu
Slide 13: Q2 and H1 2026: Reconciliation to adjusted results (unaudited)
Q2 and H1 2026: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Second quarter 2026 Reported results 535.0 340.4 132.4 132.1 (28.7) 22 % 103.4 0.50 Adjustments Business integ
Slide 14: Q2 and H1 2026: Footnotes for reconciliation to adjusted results
Q2 and H1 2026: Footnotes for reconciliation to adjusted results (unaudited) (a) Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects including subsequent integration ac
Slide 15: 2026: Quarterly income statement summary
2026: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 Net sales 492.3 535.0 1,027.4 Net sales (CER) 476.7 531.1 1,007.9 Gross profit 309.6 340.4 650.0 Gross profit margin 62.9% 63.6% 63.3% Adjusted gross profit
Slide 16: Consolidated Balance Sheets
Consolidated Balance Sheets December 31, June 30, 2026 December 31, (In $ thousands, except par value) June 30, 2026 2025 (In $ thousands, except par value) 2025 Assets (unaudited) Liabilities and equity (unaudited) Cash and cash equivalents 768,500 839,005 Current portion of long-term debt 16,517 —
Slide 17: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Six months ended Six months ended (In $ thousands) June 30, 2026 June 30, 2025 (In $ thousands) June 30, 2026 June 30, 2025 Cash flows from operating activities: Cash flows from financing activities: Net income 171,444 187,008 Capital repayment (496,
Slide 18: Q2 and H1 2026: Currency impact
Q2 and H1 2026: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q2 2026 U.S. dollar 309.4 309.4 58% 0.0 Euro 99.0 96.9 18% -2.1 British pound 17.8 17.7 3% -0.1 Japanese yen 9.2 10.2 2% 1.0 Other currencies 99.6 96.9 18%
Slide 19: Employees as of June 30, 2026
Employees as of June 30, 2026 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q2 2026 Q1 2026 Change Production 287 1,070 140 1,497 1,513 -1 % R&D 158 730 51 939 956 -2 % Sales 549 811 694 2,054 2,060 0% Marketing 77 167 65 309 320 -3 % Administration 72 437 156 665 677
Slide 20: Your contacts
Your contacts Daniel Wendorff Vice President Calendar E-mail: Head of Investor Relations ir@qiagen.com Q3 2026 results November 2026 Phone: +49 2103 29 11322 Internet: E-mail: daniel.wendorff@qiagen.com corporate.QIAGEN.com Q4 2026 results February 2027 Dr. Domenica Martorana Associate Director Shar